James A Reiffel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/241578/publications.pdf

Version: 2024-02-01

160 papers	4,354 citations	147801 31 h-index	114465 63 g-index
160 all docs	160 docs citations	160 times ranked	4905 citing authors

#	Article	IF	Citations
1	Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2019, 321, 1261.	7.4	953
2	Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes. Journal of the American College of Cardiology, 2016, 68, 2597-2604.	2.8	401
3	Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population. JAMA Cardiology, 2017, 2, 1120.	6.1	200
4	Searching for Atrial Fibrillation Poststroke. Circulation, 2019, 140, 1834-1850.	1.6	184
5	Efficacy and Safety of Prescription Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2010, 304, 2363.	7.4	183
6	The HARMONY Trial. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1048-1056.	4.8	129
7	Comparison of Autotriggered Memory Loop Recorders Versus Standard Loop Recorders Versus 24-Hour Holter Monitors for Arrhythmia Detection. American Journal of Cardiology, 2005, 95, 1055-1059.	1.6	122
8	Antiarrhythmic Effects of Omega-3 Fatty Acids. American Journal of Cardiology, 2006, 98, 50-60.	1.6	120
9	Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal, 2014, 167, 735-742.e2.	2.7	120
10	Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the antiarrhythmics versus implantable defibrillators (AVID) trial. Journal of the American College of Cardiology, 1999, 34, 325-333.	2.8	103
11	Importance of beta blockade in the therapy of serious ventricular arrhythmias. American Journal of Cardiology, 1998, 82, 9I-19I.	1.6	90
12	Atrial Fibrillation and Stroke: Epidemiology. American Journal of Medicine, 2014, 127, e15-e16.	1.5	73
13	Patient factors associated with quality of life in atrial fibrillation. American Heart Journal, 2016, 182, 135-143.	2.7	62
14	Rate versus rhythm control for management of atrial fibrillation in clinical practice: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. American Heart Journal, 2013, 165, 622-629.	2.7	61
15	Provider Specialty and Atrial Fibrillation Treatment Strategies in United States Community Practice: Findings From the ORBITâ€AF Registry. Journal of the American Heart Association, 2013, 2, e000110.	3.7	60
16	Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005358.	2.2	59
17	Drug choices in the treatment of atrial fibrillation. American Journal of Cardiology, 2000, 85, 12-19.	1.6	58
18	Propensity Score Matching: The â€˜Devil is in the Detailsâ€™ Where More May Be Hidden than You Know. American Journal of Medicine, 2020, 133, 178-181.	1.5	58

#	Article	IF	Citations
19	Effects of digoxin on sinus nodal function before and after vagal blockade in patients with sinus nodal dysfunction. American Journal of Cardiology, 1979, 43, 983-989.	1.6	46
20	Time in the Therapeutic Range for Patients Taking Warfarin in Clinical Trials. Circulation, 2017, 135, 1475-1477.	1.6	46
21	Practice Patterns Among United States Cardiologists for Managing Adults With Atrial Fibrillation (from the AFFECTS Registry). American Journal of Cardiology, 2010, 105, 1122-1129.	1.6	45
22	Drug-Device Interactions: Clinical Considerations. PACE - Pacing and Clinical Electrophysiology, 1985, 8, 369-373.	1.2	42
23	Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias11â^—Disclosure: This study was not written with support from or discussion with any pharmaceutical manufacturer.. American Journal of Cardiology, 2000, 85, 1151-1153.	1.6	42
24	Rhythm Management in Atrial Fibrillation-with a Primary Emphasis on Pharmacological Therapy: Part 2. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 742-752.	1.2	41
25	Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: A prospective study. American Heart Journal, 2009, 158, 163-169.e3.	2.7	35
26	Optimum duration of transtelephonic ECG monitoring when used for transient symptomatic event detection. Journal of Electrocardiology, 1991, 24, 165-168.	0.9	34
27	Rhythm Control Versus Rate Control andÂClinical Outcomes in Patients WithÂAtrial Fibrillation. JACC: Clinical Electrophysiology, 2016, 2, 221-229.	3.2	33
28	Effects of Aging and Gender on QT Dispersion in an Overtly Healthy Population. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 1121-1126.	1.2	32
29	Rationale and design of REVEAL AF: A prospective study of previously undiagnosed atrial fibrillation as documented by an insertable cardiac monitor in high-risk patients. American Heart Journal, 2014, 167, 22-27.	2.7	32
30	Electrophysiological Testing of Sinus Node Function: Diagnostic and Prognostic Application-Including Updated Information From Sinus Node Electrograms. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 349-365.	1.2	31
31	Issues in the use of generic antiarrhythmic drugs. Current Opinion in Cardiology, 2001, 16, 23-29.	1.8	31
32	Warfarin and Aspirin Use in Atrial Fibrillation Among Practicing Cardiologist (from the AFFECTS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 22	1.6	30
33	Sotalol for Ventricular Tachyarrhythmias: Beta-Blocking and Class III Contributions, and Relative Efficacy Versus Class I Drugs After Prior Drug Failure. American Journal of Cardiology, 1997, 79, 1048-1053.	1.6	29
34	Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	29
35	Rhythm Management in Atrial Fibrillation-With a Primary Emphasis on Pharmacological Therapy: Part 1. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 590-602.	1.2	27
36	Formulation substitution and other pharmacokinetic variability: underappreciated variables affecting antiarrhythmic efficacy and safety in clinical practice. American Journal of Cardiology, 2000, 85, 46-52.	1.6	27

#	Article	IF	Citations
37	Impact of structural heart disease on the selection of class III antiarrhythmics for the prevention of atrial fibrillation and flutter. American Heart Journal, 1998, 135, 551-556.	2.7	24
38	Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. Circulation, 2018, 138, 889-897.	1.6	23
39	Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart, 2018, 104, 1850-1858.	2.9	23
40	Rhythm Management in Atrial Fibrillation-With a Primary Emphasis on Pharmacologic Therapy: Part 3. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 1133-1145.	1.2	22
41	Antiarrhythmic drug therapy for atrial fibrillation: Are the guidelines guiding clinical practice?. Clinical Cardiology, 2006, 29, 97-102.	1.8	22
42	Cardioversion for Atrial Fibrillation: Treatment Options and Advances. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 1073-1084.	1.2	22
43	Propensity-Score Matching: Optimal, Adequate, or Incomplete?. Journal of Atrial Fibrillation, 2018, 11, 2130.	0.5	22
44	If it were only that simple. European Heart Journal, 2016, 37, 1603-1605.	2.2	18
45	The Implantable Cardioverter-Defibrillator. Circulation, 2002, 105, 1022-1024.	1.6	16
46	Is arterial stiffness a contributing factor to atrial fibrillation in patients with hypertension? A preliminary investigation. American Journal of Hypertension, 2004, 17, 213-216.	2.0	16
47	New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: What are our therapies likely to be by 2010 and beyond?. American Heart Journal, 2007, 154, 824-829.	2.7	16
48	Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 263-272.	4.0	16
49	Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart, 2020, 106, 358-364.	2.9	16
50	Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific, data-driven decision. American Journal of Cardiology, 1998, 82, 72N-81N.	1.6	15
51	Atypical Proarrhythmia with Dofetilide: Monomorphic VT and Exercise-Induced Torsade de Pointes. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 877-879.	1.2	15
52	Time in the Therapeutic Range (TTR): An Overly Simplified Conundrum. Journal of Innovations in Cardiac Rhythm Management, 2017, 8, 2643-2646.	0.5	15
53	Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation?. Current Opinion in Cardiology, 2004, 19, 58-63.	1.8	13
54	Embolic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients With Atrial Fibrillation (from the ORBIT-AF Registry). American Journal of Cardiology, 2018, 122, 1677-1683.	1.6	13

#	Article	IF	Citations
55	Drug Interactions Affecting Oral Anticoagulant Use. Circulation: Arrhythmia and Electrophysiology, 2022, 15, .	4.8	13
56	Current Status of Direct Recordings of the Sinus Node Electrogram in Man. PACE - Pacing and Clinical Electrophysiology, 1983, 6, 1143-1150.	1.2	12
57	Intravenous Amiodarone in the Management of Atrial Fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics, 1999, 4, 199-204.	2.0	12
58	Atrial Fibrillation: What Have Recent Trials Taught Us Regarding Pharmacologic Management of Rate and Rhythm Control?. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 247-259.	1.2	12
59	Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study. American Heart Journal, 2020, 219, 128-136.	2.7	12
60	â€œIn the absence of structural heart diseaseâ€¦.â€•What is it, and why does it matter in antiarrhythmic drug therapy?. American Heart Journal, 1994, 128, 626-629.	2.7	11
61	Long-term electrocardiographic safety monitoring in clinical drug development: A report from the Cardiac Safety Research Consortium. American Heart Journal, 2017, 187, 156-169.	2.7	11
62	Optimum Risk Assessment for Stroke in Atrial Fibrillation: Should We Hold the Status Quo or Consider Magnitude Synergism and Left Atrial Appendage Anatomy?. Arrhythmia and Electrophysiology Review, 2017, 6, 161.	2.4	11
63	The Utility of Ambulatory Electrocardiographic Monitoring for Detecting Silent Arrhythmias and Clarifying Symptom Mechanism in an Urban Elderly Population with Heart Failure and Hypertension: Clinical Implications. Journal of Atrial Fibrillation, 2010, 3, 193.	0.5	11
64	Practical algorithms for pharmacologic management of the post myocardial infarction patient. Clinical Cardiology, 2009, 28, 28-37.	1.8	10
65	Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. JAMA Cardiology, 2019, 4, 756.	6.1	10
66	AIMâ€•AF: A Physician Survey in the United States and Europe. Journal of the American Heart Association, 2022, 11, e023838.	3.7	10
67	Time Dependent Changes in Duration of Ventricular Repolarization After AV Node Ablation: Insights into the Possible Mechanism of Postprocedural Sudden Death. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 1539-1544.	1.2	9
68	Drug and Drug-Device Therapy in Heart Failure Patients in the Post-COMET and SCD-HeFT Era. Journal of Cardiovascular Pharmacology and Therapeutics, 2005, 10, S45-S58.	2.0	9
69	A Contemporary Look at Classic Trials in Atrial Fibrillation: What Do They Really Show and How Might They Apply to Future Therapies?. American Journal of Cardiology, 2008, 102, 3H-11H.	1.6	9
70	Frequency of Serious Arrhythmias Detected With Ambulatory Cardiac Telemetry. American Journal of Cardiology, 2010, 105, 1313-1316.	1.6	9
71	â€œPill in the Pocketâ€•Antiarrhythmic Drugs for Orally Administered Pharmacologic Cardioversion of Atrial Fibrillation. American Journal of Cardiology, 2021, 140, 55-61.	1.6	9
72	The Conversion of Paroxysmal or Initial Onset Atrial Fibrillation with Oral Ranolazine: Implications for a New "Pill-In-Pocket" Approach in Structural Heart Disease. Journal of Atrial Fibrillation, 2010, 2, .	0.5	9

#	Article	IF	Citations
73	Formulation substitution: A frequently overlooked variable in cardiovascular drug management. Progress in Cardiovascular Diseases, 2004, 47, 3-10.	3.1	8
74	Drug Therapy for Atrial Fibrillation: What Will Its Role Be in the Era of Increasing Use of Catheter Ablation?. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 108-118.	1.2	8
75	Novel Oral Anticoagulants. American Journal of Medicine, 2014, 127, e16-e17.	1.5	8
76	Rate Versus Rhythm Control Pharmacotherapy For Atrial Fibrillation: Where are We in 2008?. Journal of Atrial Fibrillation, 2008, 1, 21.	0.5	8
77	The Duration of the Sinus Node Depolarization on Transvenous Sinus Node Electrograms Can Identify Sinus Node Dysfunction and Can Suggest Its Severity. PACE - Pacing and Clinical Electrophysiology, 1989, 12, 1746-1756.	1.2	7
78	An important indirect drug interaction between dronedarone and warfarin that may be extrapolated to other drugs that can alter gastrointestinal function. American Heart Journal, 2011, 161, e5.	2.7	7
79	Does a Brugada Pattern ECG Precipitated by Excessive-Dose Flecainide Provide a Diagnosis of a Brugada Syndrome Patient and/or Contraindicate Its Use?. Circulation: Arrhythmia and Electrophysiology, 2011, 4, e47-51.	4.8	7
80	Baseline Demographics, Safety, and Patient Acceptance of an Insertable Cardiac Monitor for Atrial Fibrillation Screening: The REVEAL-AF Study. Journal of Atrial Fibrillation, 2017, 9, 1551.	0.5	7
81	Risk of Major Bleeding in Patients With Atrial Fibrillation Taking Dronedarone in Combination With a Direct Acting Oral Anticoagulant (From a U.S. Claims Database). American Journal of Cardiology, 2021, 159, 79-86.	1.6	7
82	Antiarrhythmic drugs and devices for the management of ventricular tachyarrhythmia in ischemic heart disease. American Journal of Cardiology, 1998, 82, 31I-40I.	1.6	6
83	Time to Revisit the Time in the Therapeutic Range. Journal of Atrial Fibrillation, 2017, 9, 1569.	0.5	6
84	Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007775.	4.8	6
85	Detection of Previously Unrecognized (Subclinical) Atrial Fibrillation. American Journal of Cardiology, 2020, 127, 169-175.	1.6	6
86	Drug Interactions Affecting Antiarrhythmic Drug Use. Circulation: Arrhythmia and Electrophysiology, 2022, 15, 101161CIRCEP121007955.	4.8	6
87	The Power of One: a Highly Detailed, Log-Based, Case Example that Clearly Demonstrates the Effective Use of Ranolazine for the Control of Progressive Atrial Fibrillationn. Journal of Atrial Fibrillation, 2010, 3, 304.	0.5	5
88	The Interaction Among Atrial Thromboembolism, Atrial Fibrillation, and Atrial Cardiomyopathy. American Journal of Cardiology, 2019, 124, 1317.	1.6	4
89	Changes in Management Following Detection of Previously Unknown Atrial Fibrillation by an Insertable Cardiac Monitor (from the REVEAL AF Study). American Journal of Cardiology, 2019, 124, 864-870.	1.6	4
90	Mass Screening for Atrial Fibrillation: The Hype, The Methods, and The Application. American Journal of Medicine, 2019, 132, 668-670.	1.5	4

#	Article	IF	Citations
91	Use of the HAVOC Score to Identify Patients at Highest Risk of Developing Atrial Fibrillation. Cardiology, 2021, 146, 633-640.	1.4	4
92	New versus Traditional Approaches to Oral Anticoagulation in Patients with Atrial Fibrillation. American Journal of Medicine, 2014, 127, e15.	1.5	3
93	Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. American Heart Journal, 2020, 220, 145-154.	2.7	3
94	Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: A post hoc analysis of the EURIDIS and ADONIS trials. Journal of Cardiovascular Electrophysiology, 2020, 31, 1022-1030.	1.7	3
95	Patterns of oral anticoagulation use with cardioversion in clinical practice. Heart, 2021, 107, 642-649.	2.9	3
96	Relation of Antecedent Symptoms to the Likelihood of Detecting Subclinical Atrial Fibrillation With Inserted Cardiac Monitors. American Journal of Cardiology, 2021, 145, 64-68.	1.6	3
97	When Silence Isnâ€™t Golden: The Case of â€œSilentâ€•Atrial Fibrillation. Journal of Innovations in Cardiac Rhythm Management, 2017, 8, 2886-2893.	0.5	3
98	Asymptomatic Atrial Fibrillation. Chest, 2001, 119, 628-631.	0.8	2
99	Adjunctive therapy for recurrent ventricular tachycardia in patients with implantable cardioverter defibrillators. Current Cardiology Reports, 2007, 9, 381-386.	2.9	2
100	Biomarkers and their relationship to atrial fibrillation: mechanisms, prognosis and management. Biomarkers in Medicine, 2019, 13, 1433-1438.	1.4	2
101	The Link Between CHA2DS2-VASc Score and Thromboembolic Risk in Patients Without Known Atrial Fibrillation: Are We Missing a Silent Culprit?. Journal of Atrial Fibrillation, 2020, 12, 2303.	0.5	2
102	The Use of Ranolazine in the Management of Recurrent Atrial Fibrillation After Percutaneous Radiofrequency Ablation. Journal of Atrial Fibrillation, 2012, 5, 562.	0.5	2
103	Selected Advancements in the Management of Atrial Fibrillation from the Year 2021. Journal of Innovations in Cardiac Rhythm Management, 2022, 13, 4840-4846.	0.5	2
104	Understanding Antiarrhythmic Drug Efficacy for the Clinical Practitioner: There Is More than Meets the Eye. American Journal of Medicine, 2022, 135, 822-827.	1.5	2
105	The Relationship Between Sinoatrial Conduction Time and Sinus Cycle Length Revisited. Journal of Cardiovascular Electrophysiology, 1990, 1, 290-299.	1.7	1
106	How Do Physicians Determine When to Perform an "On-Drug" Electrophysiology Study for Efficacy Determination in Patients with Sustained Ventricular Tachyarrhythmias: A Previously Unaddressed Variable That May Affect Efficacy Rates. PACE - Pacing and Clinical Electrophysiology, 1995, 18, 406-416.	1.2	1
107	Is it Rational, Reasonable or Excessive, and Consistently Applied? One View of the Increasing FDA Emphasis on Safety First for the Release and Use of Antiarrhythmic Drugs for Supraventricular Arrhythmias. Journal of Cardiovascular Pharmacology and Therapeutics, 2001, 6, 333-339.	2.0	1
108	Structural heart disease: Its importance in association with antiarrhythmic drug therapy. Clinical Cardiology, 2009, 17, II-3-II-6.	1.8	1

#	Article	IF	Citations
109	Chronic Maintenance of Sinus Rhythm in Patients with Atrial Fibrillation Using Antiarrhythmic Drugs: Update 2010. Cardiac Electrophysiology Clinics, 2010, 2, 409-418.	1.7	1
110	Pills Never Work in the Bottle. Journal of the American College of Cardiology, 2017, 70, 1584-1586.	2.8	1
111	Reader's Comments: Beyond Atrial Fibrillation Patterns as Contributors to Risk of Thromboembolism. American Journal of Cardiology, 2019, 124, 166.	1.6	1
112	Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice. Circulation: Cardiovascular Interventions, 2020, 13, e008274.	3.9	1
113	When two is not better than one: the amalgamation of atrial fibrillation and chronic obstructive pulmonary disease. European Heart Journal, 2021, 42, 3555-3557.	2.2	1
114	Clinicians May Disagree About the Usefulness of the Physical Exam, but Those Who Refute It Are Wrong. American Journal of Medicine, 2021, 134, e496.	1.5	1
115	TTR: Time in Therapeutic Range or â€œThe Troublesome Reportâ€?. Journal of Innovations in Cardiac Rhythm Management, 2019, 10, 3469-3470.	0.5	1
116	Dronedarone For Atrial Fibrillation: Unbridled Enthusiasm Or Just Another Small Step Forward?. Journal of Atrial Fibrillation, 2009, 1, .	0.5	1
117	Abstract 189: Identifying Patients at Highest Risk of Developing Atrial Fibrillation and the Role of Remote Prior Stroke: Insights From the REVEAL AF Study. Stroke, 2018, 49, .	2.0	1
118	The Concept of "Burden" in Atrial Fibrillation. Journal of Atrial Fibrillation, 2012, 4, 400.	0.5	1
119	QT Prolongation Following Ectopic Beats: Initial Data Regarding The Upper Limit Of Normal With Possible Implications For Antiarrhythmic Therapy And Concealed (Unexpressed) Long QT. Journal of Atrial Fibrillation, 2009, 1, 113.	0.5	1
120	Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDISâ€ADONIS trials. Clinical Cardiology, 2022, 45, 101-109.	1.8	1
121	OUP accepted manuscript. Europace, 2022, , .	1.7	1
122	The potential for changing prescribing patterns from warfarin to oral direct thrombin inhibitors: clinical scenarios. Reviews in Cardiovascular Medicine, 2004, 5 Suppl 5, S12-21.	1.4	1
123	Atrial Fibrillation: Is Rhythm Control Required, and If So, How, and What Is the Internist's Role?. American Journal of Medicine, 2022, 135, 939-944.	1.5	1
124	The safety of flecainide for atrial fibrillation in patients with stable coronary artery disease â€“ Fact or fallacy. American Heart Journal, 2022, 248, 163-164.	2.7	1
125	The Duration of Induced Ventricular Tachycardia as Related to Clinically Sustained Ventricular Tachycardia. Journal of Electrophysiology, 1989, 3, 127-134.	0.5	0
126	Title is missing!. Journal of Interventional Cardiac Electrophysiology, 1997, 1, 414-416.	1.0	0

#	Article	IF	Citations
127	Title is missing!. Journal of Interventional Cardiac Electrophysiology, 2000, 4, 17-19.	1.0	0
128	Microcomplex[mdash]A new incomplete heart block pattern. Journal of Electrocardiology, 2002, 35, 273-278.	0.9	0
129	Clinical pearls in cardiovascular drug therapy: Class effects and individual drug features. Progress in Cardiovascular Diseases, 2004, 47, 1-2.	3.1	0
130	Have sanctioned algorithms replaced empiric judgment in the selection process of antiarrhythmic drugs for the therapy for atrial fibrillation?. Current Cardiology Reports, 2004, 6, 365-370.	2.9	0
131	Clinical pearls in cardiovascular drug therapy: Class effects and individual drug featuresIntroductory comments. Progress in Cardiovascular Diseases, 2004, 47, 1-2.	3.1	0
132	Introduction. American Journal of Cardiology, 2008, 102, 1H-2H.	1.6	0
133	Editorial (Thematic Issue: Advances in The Therapy of Atrial Fibrillation: Incrementally Progressive But) Tj ETQq1 1 0.784314 rgBT /Ove	1.5	0
134	Abnormal ECG, Seizures, and Associated Neurological Deficits. Circulation, 2017, 135, 490-491.	1.6	0
135	To the Editorâ€" Minimal QT, not just maximal, may underlie TdP risk in women. Heart Rhythm, 2017, 14, e51.	0.7	0
136	The R-Wave Sign as a Predictor of Ventricular Tachyarrhythmias in Brugada Syndrome: The Criteria Need Verification and Clarification. American Journal of Cardiology, 2017, 120, 2299.	1.6	0
137	Selective Reporting: Silent Atrial Fibrillation and Cryptogenic Strokes. American Journal of Medicine, 2017, 130, e403.	1.5	0
138	An Incomplete Story. Journal of the American College of Cardiology, 2018, 71, 104.	2.8	0
139	Letter by Reiffel Regarding Article, â€œUnique ECG During Sinus Rhythm in a Patient With A Postmyocardial Infarction-Sustained Ventricular Tachycardiaâ€• Circulation, 2018, 138, 328-329.	1.6	0
140	Letter by Reiffel Regarding Article, â€œTreatment of Subclinical Atrial Fibrillation: Does One Plus One Always Equal Two?â€• Circulation, 2018, 138, 122-123.	1.6	0
141	When an Omission Alters the Message, Missing Facts Must be Added. American Journal of Medicine, 2019, 132, e722.	1.5	0
142	Apples will never be oranges, but when you go fishing you may get a bite. International Journal of Cardiology, 2019, 278, 155-156.	1.7	0
143	Could Different Thresholds for Tachycardic-Induced Atrial Myopathy Reflect Different Rates Between Atrial Fibrillation and Flutter?. Journal of the American College of Cardiology, 2020, 76, 2179.	2.8	0
144	The high road, the low road, and no road: She took them all. Journal of Electrocardiology, 2020, 60, 175-176.	0.9	0

#	Article	IF	Citations
145	Sinus node depolarization â€" Present during all sinus rhythms but never seen on the 12-lead ECG: An illustrative case-report that provides its recording. Journal of Electrocardiology, 2020, 60, 192-194.	0.9	0
146	QT Interval Abnormalities with Pulmonary Emboli. American Journal of Medicine, 2020, 133, e113.	1.5	0
147	When the time in the therapeutic range falls short: out of range values can be of importance. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e20-e20.	3.0	0
148	Letter by Reiffel Regarding Article, â€œEmulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiativeâ€• Circulation, 2021, 144, e160.	1.6	0
149	Pharmacologic Management of Atrial Fibrillation and Flutter. , 2011, , 165-193.		0
150	Are we at the Goal Line with the Novel Oral Anticoagulants and Have We Reached the End of the Line for Dronedarone and Vernakalant â€" or is There More to Come?. Current Cardiology Reviews, 2014, 10, 315-316.	1.5	0
151	Abstract 15680: Sinus Node Dysfunction in Associated With Higher Symptom Burden and Increased Risk of Progression to Permanent Atrial Fibrillation: Results From ORBIT-AF Registry. Circulation, 2014, 130, .	1.6	0
152	Considerations Regarding the Periprocedural Use of Oral Anticoagulation Therapy in Patients Undergoing Atrial Fibrillation Ablation. Journal of Innovations in Cardiac Rhythm Management, 2018, 9, 3282-3283.	0.5	0
153	Pharmacologic Management of Atrial Fibrillation and Flutter. Contemporary Cardiology, 2020, , 359-407.	0.1	0
154	Electrophysiological Changes of the Atrium in Patients with Lone Paroxysmal Atrial Fibrillation. Journal of Atrial Fibrillation, 2010, 3, 251.	0.5	0
155	GIANT Flutter Waves in ECG Lead V1: a Marker of Pulmonary Hypertension. Journal of Atrial Fibrillation, 2008, 1, 116.	0.5	0
156	Dronedarone: Where Does it Fit in the AF Therapeutic Armamentarium?. Journal of Atrial Fibrillation, 2013, 5, 752.	0.5	0
157	The Anticoagulated Atrial Fibrillation Patient Who Requires "Curative" Therapy for Prostate Carcinoma: a Bleeding Conundrum. Journal of Atrial Fibrillation, 2008, 1, 110.	0.5	0
158	The Importance Of Atrial Fibrillations Associated Comorbidities as Clinical Presentation and Outcome Contributors. Journal of Atrial Fibrillation, 2021, 14, 20200517.	0.5	0
159	Predictors of dronedarone plasma drug concentrations and effect on atrial fibrillation/atrial flutter recurrence: Analyses from the EURIDIS and ADONIS studies. Clinical Cardiology, 2022, 45, 119-128.	1.8	0
160	Guidelines Are Meant to Guide, But They Are Not Absolute. American Journal of Medicine, 2022, 135, e132.	1.5	0